MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-25-0089

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2025

D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer.

Giudice Anna Maria, Matlaga Stephanie, Roth Sydney L, Gladney Whitney, Groff David, Hofmann Ted J, McDaid Kendra S, Pascual-Pasto Guillem, McIntyre Brendan, Zecchino Vincent, Martinez Dan, Spear Timothy T, Wolpaw Adam J, Assenmacher Charles-Antoine, Radaelli Enrico, Pogoriler Jenny, Pawel Bruce, Barrett David, Grupp Stephan A, Maris John M, Bosse Kristopher R

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: We previously identified glypican 2 (GPC2) as a cell-surface MYCN-regulated neuroblastoma oncoprotein and developed a D3-GPC2 antibody that specifically binds a conformational, tumor-specific epitope conserved between mouse and human.

EXPERIMENTAL

DESIGN

In this study, we sought to further validate GPC2 as an immunotherapeutic target and develop Investigational New Drug application-enabling data to support the clinical translation of D3-GPC2 chimeric antigen receptor (CAR) T cells.

RESULTS

Immunohistochemistry validated that GPC2 is widely expressed on human neuroblastomas, and flow cytometry showed high levels of cell-surface GPC2 on neuroblastoma cellular models. Second-generation D3-GPC2 CAR T cells with either a 4-1BB or CD28 co-stimulatory domain were selectively activated and induced potent neuroblastoma cell cytotoxicity in several complementary in vitro co-incubation assays. Conversely, no measurable cytotoxicity or D3-GPC2 CAR T-cell activation was observed in co-incubation studies with nine primary human normal tissue cell lines. Moreover, GPC2 CAR T cells induced significant regression of GPC2-expressing neuroblastoma xenografts. No GPC2 CAR-related toxicities were noted, including in comprehensive mouse necropsies performed after GPC2 CAR T-cell administration. Finally, to explore the potential broader clinical impact of GPC2 CAR T cells, we showed that they are also potently cytotoxic to preclinical models of GPC2-expressing small cell lung cancers.

CONCLUSIONS

These data validate GPC2 as a bona fide CAR T-cell target in neuroblastoma and other cancers. The safety and preliminary efficacy of GPC2 CAR T cells are being tested in a first-in-human phase I clinical trial for children with relapsed/refractory neuroblastoma (NCT05650749).

Для цитирования: Giudice Anna Maria, Matlaga Stephanie, Roth Sydney L, Gladney Whitney, Groff David, Hofmann Ted J, McDaid Kendra S, Pascual-Pasto Guillem, McIntyre Brendan, Zecchino Vincent, Martinez Dan, Spear Timothy T, Wolpaw Adam J, Assenmacher Charles-Antoine, Radaelli Enrico, Pogoriler Jenny, Pawel Bruce, Barrett David, Grupp Stephan A, Maris John M, Bosse Kristopher R. D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. DOI: 10.1158/1078-0432.ccr-25-0089.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.